ストックスクリーナーアプリを入手
4.18
0.95%
-0.04
アフターアワーズ：
4.18
前日終値:
$4.22
開ける：
$4.28
24時間の取引高:
2.00M
Relative Volume:
0.57
時価総額：
$792.44M
収益：
-
当期純損益:
$-196.48M
株価収益率:
-3.4381
EPS:
-1.2158
ネットキャッシュフロー:
$-183.16M
1週間 パフォーマンス:
+6.63%
1か月 パフォーマンス:
-17.55%
6か月 パフォーマンス:
-18.20%
1年 パフォーマンス:
+40.27%
1日の値動き範囲:
$4.13
$4.34
1週間の範囲:
$3.875
$4.358
52週間の値動き範囲:
$2.54
$7.18
Annexon Inc Stock (ANNX) Company Profile
Compare ANNX vs VRTX, REGN, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
4.18 | 746.94M | 0 | -196.48M | -183.16M | -1.2158 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-23 | 開始されました | Chardan Capital Markets | Buy |
| 2024-03-01 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-10-30 | 開始されました | Wells Fargo | Overweight |
| 2023-05-26 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-05-25 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-09-16 | 開始されました | Jefferies | Buy |
| 2022-09-09 | 開始されました | BTIG Research | Buy |
| 2021-11-30 | 開始されました | H.C. Wainwright | Buy |
| 2021-09-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-01-26 | 開始されました | Needham | Buy |
| 2020-08-18 | 開始されました | BofA Securities | Buy |
| 2020-08-18 | 開始されました | Cowen | Outperform |
| 2020-08-18 | 開始されました | JP Morgan | Overweight |
すべてを表示
Annexon Inc (ANNX) 最新ニュース
Annexon at Cantor Fitzgerald conference: eye data, gbs progress By Investing.com - Investing.com Nigeria
ANNX: Vonaprument's phase III trial in GA shows promise for vision preservation and broad market impact - TradingView
ANNX: Phase III GA study shows strong vision preservation, with high compliance and dual primary endpoints - TradingView
ANNX: Phase III programs in GBS and GA advance toward key data and regulatory milestones, with strong differentiation - TradingView
Annexon at Wells Fargo 21st annual healthcare conference: late-stage push - Investing.com India
Annexon secures $200 million credit facility from Oxford Finance - scanx.trade
Annexon to Participate in Upcoming September Investor Conferences - Investing News Network
ANNX Maintained by JP Morgan -- Price Target Raised to $14.00 - GuruFocus
ANNEXON, INC. : JP MORGAN RAISES TARGET PRICE TO $14 FROM $10 - Moomoo
What Annexon (ANNX)'s Dual-Endpoint ARCHER II Update Means For Shareholders - Yahoo Finance
Annexon (ANNX): Pipeline Momentum Is Building, but Cash Discipline Still Runs the Story - AlphaStreet
Annexon (ANNX) Quarterly Figures: The Available Earnings Metric Delivers a Beat in the Current Update; Share Response: The Stock Loses 4.55% in the Current UpdateMargin Guidance - vinanet.vn
Annexon (ANNX) Q2 2026 Earnings Call Transcript - AOL.com
Annexon, Inc. Stock 12‑Month Price Target Raised to $15.71, Implies 198% Upside - TradingView
Annexon Reports Inducement Grants to New Employees under Nasdaq Listing Rule 5635(4) - marketscreener.com
Bank of America Corp DE Has $23.60 Million Stock Holdings in Annexon, Inc. $ANNX - MarketBeat
Annexon Inc (ANNX) Stock News Today - TradingKey
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
At $5.29, Annexon grants new employees options vesting over four years - Stock Titan
Annexon (ANNX) Adds Dual Primary Endpoint in Phase 3 Trial, Refl - GuruFocus
Annexon (ANNX) Earnings Call zu Q2 2026: ARCHER II erweitert, BLA-Einreichung im Zeitplan - TradingKey
Annexon (ANNX) Q2 2026 Earnings Call: ARCHER II Expanded, BLA Filing on Track - TradingKey
What is HC Wainwright's Estimate for Annexon Q3 Earnings? - MarketBeat
Annexon (ANNX) Is Down 6.1% After Dual Endpoint Shift in ARCHER II TrialWhat's Changed - Sahm
Annexon (NASDAQ:ANNX) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
ANNX SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
State Street Corp Boosts Annexon Inc (ANNX) Stake by 42% in June Transaction - GuruFocus
A Quick Look at Today's Ratings for Annexon(ANNX.US), With a Forecast Between $8 to $27 - Moomoo
Insider for ANNX (ANNX) plans sale of 2,000 shares after option exercise - Stock Titan
Annexon (ANNX), What Is Behind Its Latest Update? - Yahoo Finance
ANNX Upgraded by Citizens -- Rating Changed to Market Perform - GuruFocus
Annexon (NASDAQ:ANNX) Upgraded at Citizens Jmp - MarketBeat
BofA Securities Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Citizens upgrades Annexon stock rating on trial endpoint changes - Investing.com
Annexon Announces $55.3 Million Net Loss in Q2 2026 Financial Results - Kalkine Media
Form 8K Annexon Inc For: 12 August By Investing.com - Investing.com Nigeria
Annexon, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Annexon (NASDAQ: ANNX) reports $99.5M H1 2026 loss and secures new $200M debt facility - Stock Titan
Needham Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Annexon Q2 2026 Earnings Call Transcript - MarketBeat
Annexon (NASDAQ:ANNX) Issues Earnings Results, Misses Estimates By $0.05 EPS - MarketBeat
Annexon Releases Q2 2026 Financial Results - AlphaStreet
Investors Purchase High Volume of Call Options on Annexon (NASDAQ:ANNX) - MarketBeat
Annexon (NASDAQ:ANNX) Shares Gap Down on Disappointing Earnings - MarketBeat
Annexon Reports Q2 2026 Financials and Expands Vonaprument Phase 3 Trial in Geographic Atrophy - Kalkine Media
Earnings call transcript: Annexon misses Q2 2026 EPS view as shares fall premarket - Investing.com Nigeria
Transcript : Annexon, Inc., Q2 2026 Earnings Call, Aug 12, 2026 - marketscreener.com
Annexon Q2 Earnings Call Highlights - MarketBeat
ANNX: Expanded pivotal trials and strong clinical results drive regulatory and financial momentum - TradingView
Annexon reports early strength gains in tanruprubart GBS trial - scanx.trade
Annexon grants inducement options to two new employees - scanx.trade
Annexon Inc (ANNX) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.15%
大文字化:
|
ボリューム (24 時間):